David A. Siegel An2 Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q4 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in An2 Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 528,300 shares of ANTX stock, worth $596,979. This represents 0.0% of its overall portfolio holdings.
Number of Shares
528,300
Previous 120,900
336.97%
Holding current value
$596,979
Previous $129,000
456.59%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding ANTX
# of Institutions
38Shares Held
13.8MCall Options Held
0Put Options Held
0-
Bml Capital Management, LLC Zionsville, IN5.75MShares$6.5 Million4.93% of portfolio
-
Almitas Capital LLC Santa Monica, CA1.31MShares$1.48 Million0.87% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.04MShares$1.17 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny580KShares$655,1430.0% of portfolio
-
Peapod Lane Capital LLC Bedford Hills, NY579KShares$654,0720.79% of portfolio
About AN2 Therapeutics, Inc.
- Ticker ANTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 19,402,700
- Market Cap $21.9M
- Description
- AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menl...